Every Form 4 that GE HealthCare Technologies Inc. (GEHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GEHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GEHC filings page.
GE HealthCare Technologies Inc. (GEHC) reported that its Chief Financial Officer, William K. Grogan, received equity awards on September 14, 2026. He was granted 31,877 employee stock options with an exercise price of $64.25 per share, expiring September 14, 2036, which will become exercisable in three annual installments beginning September 2, 2027.
Grogan also received 62,256 restricted stock units, of which 50% vest on September 14, 2027 and 50% on September 14, 2028, and a separate award of 12,840 restricted stock units vesting 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. Each restricted stock unit represents one share of GE HealthCare common stock at settlement. No Rule 10b5-1 trading plan is reported for these awards.
GE HealthCare Technologies Inc. (GEHC) reported that officer Philip Rackliffe, CEO of AIS, had 798 shares of common stock withheld on September 3, 2026 to pay tax withholding obligations triggered by the vesting of restricted stock units. The shares were valued at $70.56 per share for this purpose, and Rackliffe now holds 41,533 shares of GE HealthCare common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
GE HealthCare Technologies Inc. (GEHC) reported that Kevin Michael O'Neill, CEO, PDx, had shares withheld on September 3, 2026 to cover tax obligations from vesting equity. 718 shares of common stock were withheld at $70.56 per share as payment of tax liability in connection with restricted stock units vesting. Following this, he holds 32,026 shares directly and 59 shares indirectly through a share incentive plan trust. No Rule 10b5-1 trading plan is reported.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Accounting Officer George A. Newcomb had 112 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations in connection with the vesting of restricted stock units. After this withholding, he holds 10,515 shares directly and 12 shares indirectly through a family member. No Rule 10b5-1 trading plan is reported for these transactions.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Technology Officer Taha Kass-Hout had 1,502 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations upon the vesting of restricted stock units. This tax-related disposition left him holding 88,467 shares of GE HealthCare common stock directly.
GE HealthCare Technologies Inc. (GEHC) reported that its General Counsel and Corporate Secretary, Frank R. Jimenez, had 1,480 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This was recorded as a disposition related to tax withholding, not an open-market sale, at a value of $70.56 per share, leaving him with 89,321 shares of GE HealthCare common stock held directly.
GE HealthCare Technologies Inc. (GEHC) reported that Chief People Officer Adam Y. Holton had 673 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This tax-withholding share disposition occurred without a Rule 10b5-1 trading plan and left him holding 19,533 shares directly.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Commercial & Growth Officer Catherine Estrampes had shares withheld to cover taxes related to equity compensation. On September 3, 2026, 508 shares of common stock were disposed of at $70.56 per share to satisfy tax withholding obligations upon the vesting of restricted stock units. After this withholding transaction, she held 23,573 shares of GE HealthCare common stock directly.
GE HealthCare Technologies Inc. (GEHC) reported that President and CEO Peter J. Arduini had 6,303 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. After this withholding, he directly holds 241,606 shares of GEHC common stock.
GE HealthCare Technologies Inc. (GEHC) disclosed that Philip Rackliffe, CEO, AIS, reported three dispositions of common stock on September 1, 2026. A total of 856 shares of common stock were withheld at $71.23 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. These are reported as payments of tax liability by delivering or withholding securities, not as open‑market sales, and no Rule 10b5-1 trading plan is indicated.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Technology Officer Taha Kass-Hout had shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
Two code F transactions were reported, covering 1,644 and 1,296 shares at $71.23 per share, for a total of 2,940 shares delivered or withheld for payment of tax liability. No Rule 10b5-1 trading plan is indicated for these transactions.
GE HealthCare Technologies Inc. (GEHC) reported that officer Frank R. Jimenez, GC & Corporate Secretary, had 3,131 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. These dispositions were not reported as being made under a Rule 10b5-1 trading plan.
GE HealthCare Technologies Inc. (GEHC) reported that Chief People Officer Adam Y. Holton had 659 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. The shares were valued at $71.23 per share for this tax-withholding transaction, which is reported as a disposition but not an open-market sale. After this event, Holton directly held 20,206 shares of GE HealthCare common stock. No transactions are reported as made under a Rule 10b5-1 trading plan.
GE HealthCare Technologies Inc. (GEHC) reported that Jeannette Bankes, CEO, Patient Care Solutions, had 1,064 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. After this tax-withholding disposition, she holds 37,293 shares of GE HealthCare common stock directly, and no Rule 10b5-1 plan is reported.
GE HealthCare Technologies Inc. (GEHC) reported that President and CEO Peter J. Arduini had 11,515 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. These are code F transactions and not open-market purchases or sales.
GE HealthCare Technologies Inc. (GEHC) reported that Chief People Officer Adam Y. Holton had 1,360 shares of common stock withheld on 2026-08-15 to satisfy tax withholding obligations in connection with the vesting of restricted stock units. After this tax-related share withholding, he directly holds 20,865 shares of GEHC common stock.
GE HealthCare Technologies Inc. director Kevin Lobo reported an open-market purchase of 10,000 shares of common stock at $64.18 per share. After this transaction, he directly owns a total of 14,363 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. reported that Philip Rackliffe, CEO of AIS, received a grant of 16,458 restricted stock units tied to its common stock. Each unit entitles him to one share at settlement. Half of the units are scheduled to vest on May 15, 2028, and the remaining half on May 15, 2029.
Following this compensation-related award, Rackliffe directly holds 43,187 shares of GE HealthCare common stock. The grant carries no cash exercise price and represents long-term equity-based compensation rather than an open-market stock purchase.
GE HealthCare Technologies Inc. executive Jeannette Bankes, CEO of Patient Care Solutions, reported a routine share withholding related to equity compensation. On May 15, 2026, 5,535 shares of common stock were withheld at $62.67 per share to cover tax obligations from vesting restricted stock units.
This was a tax-withholding disposition, not an open-market sale. Following the transaction, Bankes directly held 38,357 shares of GE HealthCare common stock.
GE HealthCare Technologies director Rodney F. Hochman reported a small open-market purchase of company stock. A family trust bought 1,618 shares of common stock at $62.03 per share. Following the transactions, he holds 19,886 shares directly and 1,618 shares indirectly through the family trust.
GE HealthCare Technologies Inc. director Phoebe L. Yang Watkin reported acquiring additional common stock. On May 8, 2026, she made an open-market purchase of 1,000 shares at a weighted average price of $63.0063 per share. After this trade, she directly held 13,702 shares.
On May 7, 2026, she also received an award of 3,586 restricted stock units. Each unit represents the right to receive one share of GE HealthCare common stock, with 100% of the units vesting on the earlier of the company’s next annual stockholders meeting or May 7, 2027, subject to the plan terms and any deferral elections.
CULP H LAWRENCE JR reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director H. Lawrence Culp Jr. reported equity-based compensation awards rather than open-market trades. He received 4,157 restricted stock units and 3,586 fully vested deferred stock units of common stock, both at no cash cost, as part of director compensation. Following these awards, he holds additional common stock directly and also indirectly through family trusts and a holding company.
GE HealthCare Technologies Inc. director Rodney F. Hochman reported equity awards under the company’s non-employee director plan. On May 7, 2026, he acquired 2,689 restricted stock units that will vest 100% on the earlier of the next annual stockholders’ meeting or May 7, 2027.
He also received 3,586 fully vested deferred stock units in lieu of 100% of his cash retainer, consistent with his election under GE HealthCare’s Non-Employee Director Compensation and Benefits Plan. Each restricted or deferred stock unit represents the right to receive one share of GE HealthCare common stock at settlement.
LESJAK CATHERINE A reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Catherine A. Lesjak received an award of 3,586 restricted stock units of GE HealthCare common stock on May 7, 2026. Each unit represents the right to receive one share of common stock at settlement and was granted at no cash cost to her.
The award will vest 100% on the earlier of GE HealthCare’s next annual meeting of stockholders or May 7, 2027. As a result of this compensation-related equity grant, Lesjak’s direct ownership reported in this filing increased to 12,702 shares of common stock, with settlement of vested units potentially deferred under the company’s Non-Employee Director Compensation and Benefits Plan.
Lobo Kevin reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Kevin Lobo reported an equity award of restricted stock units covering 3,586 shares of common stock. The award represents a grant, not an open-market purchase, and increased his direct holdings to 4,363 shares.
The filing notes that 100% of these restricted stock units will vest on the earlier of the company’s next annual meeting of stockholders or May 7, 2027. Each unit delivers one share of GE HealthCare common stock at settlement, and settlement may be deferred under the company’s Non-Employee Director Compensation and Benefits Plan.
Madden Anne T reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Anne T. Madden reported equity compensation awards in the form of company stock. She received 2,282 restricted stock units that will vest 100% on the earlier of the next GE HealthCare annual stockholder meeting or May 7, 2027. She also received 3,586 fully vested deferred stock units after electing to take her cash retainer as stock units under the Non-Employee Director Compensation and Benefits Plan. Each unit represents the right to receive one share of GE HealthCare common stock at settlement, and settlement of vested units may be deferred according to her plan elections. Following these awards, one transaction line shows she directly holds 19,479 shares of common stock.
GE HealthCare Technologies Inc. director William J. Stromberg reported a compensation-related equity grant. On May 7, 2026, he acquired 3,586 restricted stock units (RSUs), each representing one future share of common stock. These RSUs vest 100% on the earlier of the company’s next annual stockholder meeting or May 7, 2027. Stromberg can elect to defer settlement under GE HealthCare’s Non-Employee Director Compensation and Benefits Plan, meaning the actual delivery of shares can occur later according to his deferral election. Following this award, his direct holdings reported in this filing total 18,916 shares of common stock.
GE HealthCare Technologies director H. Lawrence Culp Jr. reported an open-market purchase of 80,805 shares of common stock at a weighted average price of $61.8783 per share, with individual trades between $61.50 and $62.22. Following this transaction, he indirectly holds 151,207 shares through a holding company, 328,268 shares through family trusts, and 12,699 shares directly.
GE HealthCare Technologies Inc. director William J. Stromberg reported an open-market purchase of company stock. On May 6, 2026, he bought 1,000 shares of common stock at $61.6892 per share, bringing his directly held ownership to 15,330 shares after the transaction.
GE HealthCare Technologies Inc. Chief Financial Officer James Saccaro purchased 3,310 shares of Common Stock in an open-market transaction on May 1, 2026 at a weighted average price of $60.5997 per share. Following this purchase, he directly owns 87,471 shares. The filing notes the shares were bought in multiple trades at prices ranging from $60.59 to $60.60 per share.
GE HealthCare Technologies Inc. General Counsel and Corporate Secretary Frank R. Jimenez reported an open-market purchase of 1,750 shares of common stock at a price of $60.45 per share. Following this transaction, he directly owns 93,932 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini made an open-market purchase of company stock. On this date, he bought 4,169 shares of common stock at $59.925 per share.
After this transaction, Arduini directly owns 259,424 shares of GE HealthCare common stock. This filing shows a net increase in his personal shareholding through a straightforward open-market purchase.
Lobo Kevin reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Kevin Lobo received an equity award of 777 restricted stock units of common stock. These RSUs were granted at no cash cost to him and represent compensation rather than an open-market purchase or sale.
According to the award terms, 100% of the 777 restricted stock units will vest on the earlier of GE HealthCare’s next annual meeting of stockholders or March 13, 2027. Each vested unit entitles him to receive one share of GE HealthCare common stock, and settlement may be deferred under the company’s non-employee director compensation plan.
Bankes Jeannette reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Jeannette Bankes, CEO of Patient Care Solutions, received new equity awards. On March 2, 2026, she was granted an employee stock option for 18,038 shares of common stock and 6,861 restricted stock units, both at no cash cost.
The restricted stock units each represent one share of GE HealthCare common stock and are scheduled to vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option becomes exercisable on the same 33/33/34 schedule. Following these awards, she directly holds 43,892 shares of common stock and 18,038 options.
GE HealthCare Technologies Inc. reported that its General Counsel and Corporate Secretary, Frank R. Jimenez, received new equity awards. He was granted an employee stock option covering 28,697 shares of common stock at an exercise price of $0.00 per share, and a separate award of 10,915 shares of common stock, reported as a grant or award acquisition.
The common stock award represents restricted stock units, each equal to one share of GE HealthCare common stock. For that award, 33% will vest on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option vests on the same schedule, with 33% becoming exercisable on each of those first two dates and 34% on the third. After these transactions, Jimenez directly holds 28,697 employee stock options and 92,182 shares of common stock.
Kass-Hout Taha reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Chief Technology Officer Taha Kass-Hout received equity awards on March 2, 2026. He was granted an employee stock option for 34,847 shares and 13,254 shares of common stock as a restricted stock unit award, vesting in stages from September 2, 2027 through September 2, 2029.
GE HealthCare Technologies Inc. Chief People Officer Adam Y. Holton reported awards of company equity on March 2, 2026. He received an employee stock option for 14,348 shares of common stock at an exercise price of $0.00 per share, bringing his directly held options to 14,348.
On the same date, he was granted 5,457 shares of common stock, increasing his directly held common shares to 22,225. The common stock award consists of restricted stock units, with 33% vesting on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options follow the same 33%/33%/34% vesting and exercisability schedule on those dates.
GE HealthCare Technologies Inc. Chief Accounting Officer George A. Newcomb reported equity awards from the company. He received an employee stock option for 3,443 shares of common stock at an exercise price of $0.00 per share, and an award of 1,309 restricted stock units, each representing one share of common stock at settlement.
According to the award terms, 33% of the restricted stock units will vest on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029. The stock option becomes exercisable on the same schedule: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. After these transactions, he directly owned 10,627 shares of common stock and had an additional 12 shares held indirectly by a family member.
GE HealthCare Technologies reported that Kevin Michael O'Neill, CEO of PDx, received equity awards on March 2, 2026. He was granted 17,218 employee stock options at an exercise price of $0.00 per share and 6,549 shares of common stock as a stock award, all held directly.
The options will become exercisable in three installments of 33%, 33%, and 34% on September 2, 2027, September 2, 2028, and September 2, 2029. A separate restricted stock unit award will vest on the same 33%, 33%, 34% schedule. O'Neill also has 59 shares held indirectly through a share incentive plan trust.
Rackliffe Philip reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. granted equity awards to executive Philip Rackliffe, CEO of AVS. He received 24,598 employee stock options with a right to buy GE HealthCare common stock and 9,356 restricted stock units, each representing one share upon settlement.
The stock options and restricted stock units vest over three years, with 33% vesting or becoming exercisable on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. These awards are part of his direct ownership and represent compensation rather than open-market purchases.
GE HealthCare Technologies Inc. reported that Roland Rott, CEO of Imaging, received new equity awards. He was granted employee stock options for 22,548 shares at an exercise price of $0.00 per share and 8,576 shares of common stock as a stock-based award.
The restricted stock units for 8,576 shares will vest in stages, with 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The 22,548 stock options follow the same 33%/33%/34% exercisability schedule on those dates.
SACCARO JAMES reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Chief Financial Officer James Saccaro received equity awards on March 2, 2026. He was granted 32,797 employee stock options and 12,475 restricted stock units, each at a price of $0.00 per unit.
The restricted stock units vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options become exercisable on the same 33%/33%/34% schedule over those dates. Following the stock award, Saccaro directly holds 84,161 shares of common stock and 32,797 options.
Arduini Peter J reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that President and CEO Peter J. Arduini received new equity awards. He was granted an employee stock option covering 129,140 shares of GE HealthCare common stock and 49,120 restricted stock units, each representing one share of common stock at settlement.
According to the vesting schedule, 33% of both the restricted stock units and the stock options will vest or become exercisable on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029. Following the stock grant, Arduini directly owned 255,255 shares of common stock.
GE HealthCare Technologies Chief Accounting Officer George A. Newcomb reported equity compensation activity tied to performance stock units. On February 12, 2026, he acquired 2,523 shares of common stock at $0 per share when PSUs granted on March 1, 2023 vested after performance criteria were certified.
On the same date, 802 shares at $79.2 per share were withheld to cover tax obligations arising from the PSU vesting, a non-market disposition. After these transactions, he directly owned 9,318 shares of common stock and indirectly held 12 additional shares through a family member.
GE HealthCare Technologies Inc. CEO Kevin Michael O'Neill reported equity award activity in company stock. On February 12, 2026, he acquired 6,938 shares of common stock at $0 per share through the vesting of previously granted performance stock units after performance criteria were certified.
To cover related tax withholding obligations from this vesting, 3,261 shares were disposed of at a price of $79.2 per share. Following these transactions, O'Neill directly held 26,195 shares of GE HealthCare common stock and indirectly held 59 shares through a share incentive plan trust.
GE HealthCare Technologies Inc. CEO Philip Rackliffe reported equity transactions tied to performance stock units (PSUs). On February 12, 2026, 3,154 shares of common stock were acquired at $0 per share upon PSU vesting after performance criteria were certified.
To cover related tax obligations, 1,174 shares were disposed of through a tax-withholding transaction at $79.2 per share. Following these transactions, Rackliffe directly owned 17,373 shares of GE HealthCare common stock.
GE HealthCare Technologies executive Roland Rott, CEO of Imaging, reported equity award activity in company stock. On February 12, 2026, he acquired 7,885 shares of common stock at $0 per share from the vesting of previously granted performance stock units after performance goals were certified. On the same date, 3,943 shares were disposed of at $79.2 per share to cover tax withholding tied to that vesting, a non-open-market transaction. After these entries, he directly owned 32,506 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc.’s Chief Technology Officer, Kass-Hout Taha, reported equity transactions in company common stock. On February 12, 2026, he acquired 23,339 shares at $0 per share through the vesting of performance stock units granted on March 1, 2023, after performance criteria were certified as met. On the same date, 7,787 shares were disposed of at $79.20 per share to cover tax withholding obligations related to this vesting. Following these transactions, he directly owned 79,655 shares of GE HealthCare common stock.
GE HealthCare Technologies’ GC & Corporate Secretary Frank R. Jimenez reported equity compensation activity involving company common stock. On February 12, 2026, he acquired 22,078 shares at $0 per share through the vesting of performance stock units granted on March 1, 2023, after performance goals were certified as met. On the same date, 8,357 shares were disposed of at $79.20 per share to cover tax withholding obligations tied to this vesting, a non‑market, tax-related transaction. Following these entries, he directly owned 81,267 shares of GE HealthCare common stock.
SACCARO JAMES reported multiple insider transaction types in a Form 4 filing for GEHC. The filing lists transactions totaling 31,180 shares at a weighted average price of $79.20 per share. Following the reported transactions, holdings were 71,686 shares.